MedTrace Logo

Docetaxel in Hormone Refractory Prostate Cancer (HRPC)[Weekly or 3weekly TAX + Prednisone in HRPC]

NCT00268710 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2009-12-07

No results posted yet for this study

Summary

Primary objectives:

* To determine the response rate, measurable and non measurable, to Taxotere® in the second line setting.

Secondary objectives:

* To evaluate the overall safety and toxicity of Taxotere®/prednisone combination as second line therapy in HRPC
* To evaluate PSA response (PSA: Prostate Specific Antigen)
* To evaluate symptomatic response
* To evaluate Quality of life
* To evaluate patient safety of weekly versus q3 weekly regimens of Taxotere®.

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

docetaxel

Sponsors & Collaborators

  • Canadian Urologic Oncology Group

    collaborator OTHER

  • Sanofi

    lead INDUSTRY

Principal Investigators

  • Monique Furlan · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2006-03-31
Completion
2006-03-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00268710 on ClinicalTrials.gov